[Federal Register Volume 71, Number 107 (Monday, June 5, 2006)]
[Notices]
[Page 32349]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-8715]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Clinical Laboratory Improvement Advisory Committee

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following committee meeting.

    Name: Clinical Laboratory Improvement Advisory Committee 
(CLIAC).
    Times and Dates: 8:30 a.m.-5 p.m., June 20, 2006. 8:30 a.m.-3 
p.m., June 21, 2006.
    Place: Sheraton Midtown Atlanta Hotel at Colony Square, 188 14th 
Street, NE., Atlanta, Georgia 30361, Telephone: (404) 892-6000.
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 100 people.
    Purpose: This Committee is charged with providing scientific and 
technical advice and guidance to the Secretary of Health and Human 
Services, the Assistant Secretary for Health, and the Director, CDC, 
regarding the need for, and the nature of, revisions to the 
standards under which clinical laboratories are regulated; the 
impact on medical and laboratory practice of proposed revisions to 
the standards; and the modification of the standards to accommodate 
technological advances.
    Matters To Be Discussed: Updates from CDC, the Centers for 
Medicare & Medicaid Services, and the Food and Drug Administration; 
presentations and discussion concerning gynecologic cytology 
laboratory practice and proficiency testing; and a report from the 
CLIAC Cytology Proficiency Testing Workgroup and discussion of the 
Workgroup's proposals related to such. Agenda items are subject to 
change as priorities dictate.
    Providing Oral or Written Comments: It is the policy of CLIAC to 
accept written public comments and provide a brief period for oral 
public comments whenever possible. Oral Comments: In general, each 
individual or group requesting to make an oral presentation will be 
limited to a total time of five minutes (unless otherwise 
indicated). Speakers must also submit their comments in writing for 
inclusion in the meeting's Summary Report. To assure adequate time 
is scheduled for public comments, individuals or groups planning to 
make an oral presentation should, when possible, notify the contact 
person below at least one week prior to the meeting date. Written 
Comments: For individuals or groups unable to attend the meeting, 
CLIAC accepts written comments until the date of the meeting (unless 
otherwise stated). However, the comments should be received at least 
one week prior to the meeting date so that the comments may be made 
available to the Committee for their consideration and public 
distribution. Written comments, one hard copy with original 
signature, should be provided to the contact person below. Written 
comments will be included in the meeting's Summary Report.
    Contact Person for Additional Information: Devery Howerton, 
Acting Chief, Laboratory Practice Standards Branch, Division Public 
Health Partnerships--Laboratory Systems, National Center for Health 
Marketing, Coordinating Center for Health Information and Service, 
CDC, 1600 Clifton Road, NE., Mailstop G-23, Atlanta, Georgia 30333; 
telephone (404) 718-1016; fax (404) 718-1080; or via e-mail at 
[email protected].
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register.
    Notices pertaining to announcements of meetings and other 
committee management activities, for CDC and the Agency for Toxic 
Substances and Disease Registry.

    Dated: May 30, 2006.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
 [FR Doc. E6-8715 Filed 6-2-06; 8:45 am]
BILLING CODE 4163-18-P